Future studies of factors that affect adherence to insulin treatment, and initiatives aiming to improve it, could allow more persons with T2DM to achieve optimal glycemic control and thus fully benefit from treatment with basal insulin analogues. This evidence concerns the gene INS and type 2 diabetes mellitus.